» Articles » PMID: 29658569

β‑catenin Nuclear Translocation Induced by HIF‑1α Overexpression Leads to the Radioresistance of Prostate Cancer

Overview
Journal Int J Oncol
Specialty Oncology
Date 2018 Apr 17
PMID 29658569
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia-inducible factor‑1α (HIF‑1α) is known to play crucial roles in tumor radioresistance; however, the molecular mechanisms responsible for the promotion of tumor radioresistance by HIF‑1α remain unclear. β‑catenin is known to be involved in the metastatic potential of prostate cancer (PCa). In this study, to investigate the role of HIF‑1α and β‑catenin in the radioresistance of PCa, two PCa cell lines, LNCaP and C4‑2B, were grouped as follows: Negative control (no treatment), HIF‑1α overexpression group (transfected with HIF‑1α overexpression plasmid) and β‑catenin silenced group (transfected with HIF‑1α plasmids and β‑catenin-shRNA). Cell proliferation, cell cycle, cell invasion and radiosensitivity were examined under normal or hypoxic conditions. In addition, radiosensitivity was examined in two mouse PCa models (the LNCaP orthotopic BALB/c-nu mice model and the C4‑2B subcutaneous SCID mice model). Our results revealed that in both the LNCaP and C4‑2B cells, transfection with HIF‑1α overexpression plasmid led to an enhanced β‑catenin nuclear translocation, while β‑catenin silencing inhibited β‑catenin nuclear translocation. The enhanced β‑catenin nuclear translocation induced by HIF‑1α overexpression resulted in an enhanced cell proliferation and cell invasion, an altered cell cycle distribution, decreased apoptosis, and improved non‑homologous end joining (NHEJ) repair under normal and irradiation conditions. Similar results were observed in the animal models. HIF‑1α overexpression enhanced β‑catenin nuclear translocation, which led to the activation of the β‑catenin/NHEJ signaling pathway and increased cell proliferation, cell invasion and DNA repair. These results thus suggest that HIF‑1α overexpression promotes the radioresistance of PCa cells.

Citing Articles

Myriad factors and pathways influencing tumor radiotherapy resistance.

Mi L, Zhang H Open Life Sci. 2024; 19(1):20220992.

PMID: 39655194 PMC: 11627069. DOI: 10.1515/biol-2022-0992.


Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.

Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A Cancer Metastasis Rev. 2024; 43(1):229-260.

PMID: 38374496 DOI: 10.1007/s10555-024-10168-9.


Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.

Bigos K, Quiles C, Lunj S, Smith D, Krause M, Troost E Front Oncol. 2024; 14:1331355.

PMID: 38352889 PMC: 10861654. DOI: 10.3389/fonc.2024.1331355.


CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer.

Tang J, Li J, Lian J, Huang Y, Zhang Y, Lu Y J Adv Res. 2023; 61:239-251.

PMID: 37734566 PMC: 11258662. DOI: 10.1016/j.jare.2023.09.011.


siRNA-mediated stathmin1 silencing inhibits proliferation of prostate carcinoma cell line.

Aksoy A, Gokturk S, Etem Onalan E, Tektemur A, Artas G, Varoglu A Turk J Biol. 2023; 46(3):239-250.

PMID: 37529254 PMC: 10388118. DOI: 10.55730/1300-0152.2612.


References
1.
Johansson S, Astrom L, Sandin F, Isacsson U, Montelius A, Turesson I . Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer. Prostate Cancer. 2012; 2012:654861. PMC: 3399336. DOI: 10.1155/2012/654861. View

2.
Orsulic S, Huber O, Aberle H, Arnold S, Kemler R . E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci. 1999; 112 ( Pt 8):1237-45. DOI: 10.1242/jcs.112.8.1237. View

3.
Brown J, Giaccia A . The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998; 58(7):1408-16. View

4.
Brown J, Wilson W . Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; 4(6):437-47. DOI: 10.1038/nrc1367. View

5.
Wang J, Zhou D, He X, Wang Y, Hu W, Jiang L . Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells. Cell Mol Biol (Noisy-le-grand). 2011; 57 Suppl:OL1606-13. View